Clementia Pharmaceuticals Inc. priced its IPO of 8 million common shares at $15 per share.

The company also granted underwriters a 30-day option to buy up to an additional 1.2 million of the shares offered.

The shares will begin trading on the Nasdaq Global Select Market on Aug. 2 under the CMTA symbol. The offering is expected to close on Aug. 7.

Morgan Stanley & Co. LLC and Leerink Partners LLC are acting as book-running managers for the offering, while Wedbush Securities Inc. and BTIG LLC are acting as co-managers.